Skip to main content
GC CELL CORPORATION logo

GC CELL CORPORATION — Investor Relations & Filings

Ticker · 144510 ISIN · KR7144510005 KO Manufacturing
Open in API
Filings indexed 260 across all filing types
Latest filing 2024-08-14 Regulatory Filings
Country KR South Korea
Listing KO 144510

About GC CELL CORPORATION

http://gccell.com/en/main.do

GC CELL CORPORATION specializes in cell and gene therapy, providing a fully integrated value chain from research to commercialization. The company's core offerings include end-to-end Contract Development and Manufacturing Organization (CDMO) services for autologous and allogeneic cell therapies, comprehensive bio-logistics, and cell banking. Its integrated model supports partners throughout the entire drug life cycle, from initial development and manufacturing to clinical trials and commercial distribution. In addition to its service-based solutions, GC CELL develops proprietary cell therapy products, including Immuncell-LC, an adjuvant therapy for hepatocellular carcinoma. The company focuses on advancing treatments in areas such as immune-oncology and delivering customized solutions to enhance patient outcomes.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험계획승인신청등결정) (GCC2005의 국내 제 1상 임상시험계획 승인)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from a Korean company (GC Cell) submitted to the Korea Exchange (KRX) regarding the approval of a Phase 1 clinical trial (GCC2005). It details the clinical trial design, regulatory approval from the Ministry of Food and Drug Safety (MFDS), and associated risks. Since it is a specific regulatory disclosure of a material business event (clinical trial approval) that does not fit into categories like financial reports, dividends, or M&A, it is classified as a Regulatory Filing (RNS).
2024-08-14 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 1% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for GC Cell, detailing quarterly financial performance (revenue, operating profit, net income) for 2024 Q2. It is a standard regulatory disclosure of preliminary financial results, which fits the definition of an Earnings Release (ER). H1 2024
2024-08-05 Korean
투자판단관련주요경영사항 (CAR-NK 고형암 치료제 공동연구개발 계약 해지)
M&A Activity Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It specifically announces the termination of a joint research and development contract for a CAR-NK solid tumor treatment between GC Cell and Artiva Biotherapeutics. Since this is a formal disclosure of a significant corporate event (contract termination) filed with a regulatory body, it falls under the 'Regulatory Filings' category.
2024-06-25 Korean
투자판단관련주요경영사항(임상시험계획변경승인) (AB-201의 호주 제 1상 임상시험계획 변경승인)
Legal Proceedings Report Classification · 1% confidence The document is a formal regulatory disclosure from a Korean company (GC Cell) regarding a change in clinical trial plans (AB-201). It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) filed with the Korea Exchange (KRX). Since it is a specific regulatory announcement regarding clinical trial status and does not fit into the other specialized categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2024-06-25 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청) (AB-201의 호주 제1상 임상시험계획 변경승인 신청)
Regulatory Filings Classification · 1% confidence The document is a formal regulatory filing from a Korean company (GC Cell) submitted to the Korea Exchange (KRX). It details a 'Major Management Matter' regarding an application for an amendment to a clinical trial plan (AB-201). Since this is a specific regulatory disclosure of a material event (clinical trial update) that does not fit into categories like financial reports, earnings releases, or shareholder meeting materials, it falls under the 'Regulatory Filings' category.
2024-05-20 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'GC Cell' (주)지씨셀, covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial and operational information, including business descriptions, product performance, production capacity, and risk management policies. As it is a comprehensive financial report for a period shorter than a full fiscal year, it falls under the 'Interim / Quarterly Report' category. Q1 2024
2024-05-16 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.